PF-Atlas › Clinical Trials › NCT01614470

Study of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CF Transmembrane Conductance Regulator Gating Mutation

Ivacaftor · Phase 3

Registry ID
NCT01614470
Phase
Phase 3
Status
Completed
Drug / intervention
Ivacaftor
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2012-07
Enrollment
39
Locations
12

About this trial

The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have a non-G551D cystic fibrosis transmembrane regulator (CFTR) gating mutation (any one of the following CFTR mutations: G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D).

View NCT01614470 on ClinicalTrials.gov →

Explore related

All Ivacaftor trialsAll IPF trials

Related trials

ivacaftor — NCT02445053Ivacaftor — NCT00953706Ivacaftor — NCT01614457Ivacaftor — NCT01705145Ivacaftor — NCT02934698Ivacaftor — NCT03068312
Medical disclaimer. This page summarizes public trial data for NCT01614470 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.